News and Announcements
EpiAxis Therapeutics & Peter Thiel-backed Peptilogics Enter Strategic Partnership
- Published September 23, 2022 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Sydney, Australia & Pittsburgh, USA: Cancer epigenetics company EpiAxis Therapeutics and computational biology company Peptilogics have entered a collaboration to leverage AI for drug discovery to inhibit epigenetic oncology targets, aiming to reprogram cancer cells and drive immune reinvigoration.
EpiAxis Therapeutics is a leading epigenetics company with a focus on the treatment, diagnosis, and monitoring of cancer and the prevention of its recurrence. Peptilogics is a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases. Peptilogics is backed by visionary investors in life science and technology including Peter Thiel, Presight Capital, Founders Fund, CARB-X, and Cystic Fibrosis Foundation.
The collaboration will combine EpiAxis Therapeutics’ deep epigenetic expertise and Peptilogics’ AI platform (Nautilus™) to advance drug discovery for cancers that escape existing therapies through epigenetic change, including metastatic breast cancer.
Dr Jeremy Chrisp, CEO of EpiAxis Therapeutics, commented on the significance of the collaboration: “We are very pleased to be partnering with Peptilogics to use their receptor pharmacology and AI computing expertise to accelerate innovation and hopefully expand our candidate pipeline.
“An AI-driven paradigm shift is happening in drug discovery and EpiAxis is excited to be working with Peptilogics at the forefront of applying AI to the highly valuable space around novel epigenetic targets.”
Peptilogics’ Nautilus™ platform enables in silico predictive peptide design across diverse targets to efficiently access new functional chemical space and design therapeutics.
Additionally, Peptilogics’ purpose-built supercomputer accelerates model development, prediction, and evaluation of peptide sequences to produce higher quality hits with greater chance of success.
“We are equally delighted to launch this collaboration with EpiAxis Therapeutics, a pioneer in the field of epigenetic cancer therapy,” said Nicholas Nystrom PhD, Chief Technology Officer of Peptilogics.
“We will focus on lead optimization using Peptilogics’ Nautilus™ platform, which combines proprietary deep generative models, predictive models, and biophysical simulation to design multiparameter-optimized peptides with potential to address historically challenging and novel drug targets.”
“With EpiAxis Therapeutics, we will explore further optimizing lead candidates for epigenetic cancer treatment, with the goal of reducing the risk, time, and cost for epigenetic drug design and development.”
The strategic partnership follows the recent publication of the results of EpiAxis’ pioneering clinical trial EPI-PRIMED in leading cancer journal Frontiers in Oncology.
The study was the first time an epigenetic inhibitor has been used in combination with chemotherapy to treat metastatic cancer. The results provided proof of concept for the company’s drug development program for its first-in-class therapies to inhibit nuclear LSD1.
For more information about the partnership between EpiAxis Therapeutics and Peptilogics, please contact:
Dr Jeremy Chrisp
- Phone: +61 421 012 268
- [email protected]
Liz Boten
- Phone: +1 720 219 5107
- E: [email protected]
ABOUT EPIAXIS THERAPEUTICS
EpiAxis is a leading drug development company that aims to make cancer a chronic disease rather than a fatal one, by using epigenetic science to create a completely different approach to cancer treatment. Our therapies work differently to existing – and often toxic – treatments by reprogramming the cancer cells back towards normal cells. For more information about EpiAxis visit www.epiaxistherapeutics.com
ABOUT PEPTILOGICS
Peptilogics engineers peptide therapeutic candidates to radically improve the treatment landscape for patients with life-threatening diseases. Through biological and pharmaceutical expertise, novel artificial intelligence algorithms, and purpose-built super-computing, Peptilogics is advancing an extensive therapeutic pipeline and accelerating discovery efforts at a pace and scale that was previously impossible. Peptilogics is backed by visionary investors in life science and technology including Peter Thiel, Presight Capital, Founders Fund, CARB-X, and Cystic Fibrosis Foundation. For more information about Peptilogics, visit www.peptilogics.com
Company Updates
Capital Flight or Policy Oversight? The $180M Seismic Shift Threatening Australian Innovation
A formal Senate submission by Wholesale Investor / CapitalHQ details the alarming real-world reactions of 260 founders and investors to proposed federal tax changes. With 91% of sophisticated investors scaling back local allocations and over $180M already paused or redirected offshore, the report warns of a structural funding crisis threatening the future of Australian deep tech, private equity, and startup innovation.
The Yield Illusion: Inside RAM’s Strategy to Withstand the Credit Shakeout
As interest rates reprice in 2026, the rush into private credit has created a dangerous trap for yield-hungry investors. Real Asset Management Group CEO Scott Kelly exposes the “yield illusion” dominating the market and explains why an origination-led, low-arrears mortgage strategy is the ultimate defense against an impending credit shakeout.
Office sector ‘unloved’ no more: Acure’s $80m Brisbane bet
While institutional investors remain wary of the office sector, Acure Asset Management is doubling down. Founder Angelo Del Borrello explains the “unloved” asset strategy behind his latest $80 million Brisbane acquisition and why the 2032 Olympics are creating a unique arbitrage opportunity for private syndicates.
Backed By Leading Investment Groups and Family Offices
